DLL3 and small cell lung carcinoma: The anti‐DLL3/CD3 Bispecific T cell engager (BiTE) antibody (AMG 757) and a chimeric antigen receptor T cell therapy targeting DLL3 (AMG119) have been clinically evaluated in phase 1 clinical trials for the treatment of relapsed/refractory SCLC.28